Angelman sindromearen tratamendurako itu terapeutikoen bila: USP9X deubikuitinasa jomugan

• Elu, Nagore ^[1] ; Ramirez, Juanma ; Lectez, Benoit ^[1] ; Osinalde, Nerea ; Mayor, Ugo
  1. [1] Universidad del pais vasco
• Localización: Osagaiz: osasun-zientzien aldizkaria, ISSN-e 2530-9412, Vol. 3, Nº. 1 (Ekaina), 2019, págs. 71-78
• Idioma: euskera
• Títulos paralelos:
  • Searching for Angelman syndrome therapeutical targets: deubiquitinase USP9X in the spotlight
• Enlaces
  • Texto completo
• Resumen
  • euskara

     UBE3A proteinaren gabeziak Angelman sindromea sorrarazten du. Proteina horrek zelulako beste proteina batzuk ubikuitinatzen ditu, haien funtzioa erregulatuz. Hortaz, UBE3A falta denean, bere substratuak —DDI1 kasu— gutxiago ubikuitinatuko dira, ondorio larriak ekarriz. Horrez gain, deubikuitinasa deritzen proteinek substratuen ubikuitina kentzean, egoera larritzen da. Lan honetan DDI1 substratutik ubikuitina ketzen duen proteinetako bat —USP9X— identifikatu dugu eta itu terapeutiko gisa aurkeztu dugu, zeren berau inhibitzeak DDI1 proteinaren ubikuitinazioa emendatu eta gaixotasunaren eredu diren eulien sintomatologia hobetzen baitu. * Lan honek artikulu onenaren saria lortu du Ikergazte 2019an

  • English

    Lack of UBE3A protein causes Angelman syndrome. This protein is in charge of ubiquitinating other proteins in the cell. Therefore, when there is lack of UBE3A, its substrates —such as DDI1— will be less ubiquitinated, negatively affecting cell equilibrium. Moreover, proteins named deubiquitinases remove ubiquitin from the substrates, making the scenario even worse. In this work we have identified one of the proteins —USP9X— that deubiquitinates DDI1 and presented it as a therapeutical target, since its inhibition enhances DDI1 ubiquitination and improves the climbing ability of Angelman syndrome model flies.